BioMark Diagnostics Inc
CNSX:BUX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioMark Diagnostics Inc
Net Income (Common)
BioMark Diagnostics Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioMark Diagnostics Inc
CNSX:BUX
|
Net Income (Common)
-CA$1.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
MedMira Inc
XTSX:MIR
|
Net Income (Common)
-CA$3.5m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-1%
|
|
|
G
|
Gemina Laboratories Ltd
CNSX:GLAB
|
Net Income (Common)
-CA$4.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BioMark Diagnostics Inc
Glance View
BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-11-03. The Company’s cancer diagnostic solutions can help detect, monitor and assess treatment for cancer. Its cancer diagnostics technology platform leverages Omics and machine learning, which allows for early cancer detection. The firm is focused on bringing its cancer diagnostic kits and detection solution to commercialization standards. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The firm has developed a liquid biopsy metabolic panel assay. This metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.
See Also
What is BioMark Diagnostics Inc's Net Income (Common)?
Net Income (Common)
-1.7m
CAD
Based on the financial report for Dec 31, 2025, BioMark Diagnostics Inc's Net Income (Common) amounts to -1.7m CAD.
What is BioMark Diagnostics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-27%
Over the last year, the Net Income (Common) growth was 10%. The average annual Net Income (Common) growth rates for BioMark Diagnostics Inc have been 6% over the past three years , -27% over the past five years .
